Xoma granted Servier rights outside the U.S. and Japan to develop and commercialize XOMA-052 for Behcet's uveitis, inflammatory and cancer indications.

Xoma Corp.

U.S. / Small-Cap Biopharma (<$1 billion)

$111.8m on 12/31/2010 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Servier

France / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced